CNR1 anticorps (Extracellular, N-Term)

N° du produit ABIN7884842

Cet anticorps anti-CNR1 Polyclonal Lapin (ABIN7884842) détecte spécifiquement CNR1 dans WB, IHC, IF, FACS, LCI et IC. L’anticorps est réactif avec des échantillons de Humain, Rat et Souris.

Aperçu rapide pour CNR1 anticorps (Extracellular, N-Term) (ABIN7884842)

Antigène: CNR1 (Cannabinoid Receptor 1 (CNR1))

Reactivité: Humain, Rat, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CNR1 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Flow Cytometry (FACS), Live Cell Imaging (LCI), Immunochromatography (IC)

Classe de qualité: Carrier-free

Détail du produit anti-CNR1 anticorps

Épitope: AA 84-99, Extracellular, N-Term

Fonction: A Rabbit Polyclonal Antibody to Cannabinoid Receptor 1

Homologie: Human - identical, mouse - 15,16 amino acid residues identical

Purification: Affinity purified on immobilized antigen.

Immunogène: NKSLSSFKENEENIQC, corresponding to amino acid residues 84-99 of rat CB1 receptor

Isotype: IgG

Information d'application

Indications d'application:

WB: 1:200

FC: 2.5 μg per reaction

ICC: The optimal concentration should be determined by the user

IHC: 1:100

IP: The optimal concentration should be determined by the user

Commentaires:

Negative Control: (ABIN7235028)

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: 0.2 mL double distilled water (DDW)

Concentration: 1 mg/mL

Buffer: PBS pH 7.4

Agent conservateur: Without preservative

Stock: -20 °C

Stockage commentaire: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C

Détails sur CNR1

Antigène: CNR1 (Cannabinoid Receptor 1 (CNR1))

Autre désignation: CB1

Sujet:

Synonyms: CB1, CB-R, CNR1, CB1R, CANN6, Brain-type cannabinoid receptor, Central cannabinoid receptor

Description: Cannabinoids have been used in Eastern medicine for many years as pain relievers.1 Δ9-tetrahydrocannabinol (THC), the major psychoactive compound in marijuana and hashish, has been shown to interact with two specific cannabinoid receptors: cannabinoid receptor 1 (CB1 receptor) and cannabinoid receptor 2 (CB2 receptor).2 The cannabinoid receptors can be distinguished by their amino acid sequences, signaling mechanisms, and tissue distributions.2 Both receptors belong to the G-protein coupled receptor (GPCR) superfamily. CB1 was shown to modulate several Ca2+ and K+ ion channels.2,3CB1 is primarily expressed in the central nervous system. However, expression of CB1 is also detected in the peripheral terminals, in non-neuronal peripheral tissues such as uterus, testes, spleen, as well as in cells of the immune system.3,4CB1 is implicated in many cellular functions such as neurotransmitter release, pain relief, cancer, and obesity.5,6 Growth inhibition of tumor cells was demonstrated following mixed CB1/CB2 agonist treatment in both prostate and non-melanoma skin cancers.5,6 Through their interaction with CB1, cannabinoid compounds stimulate appetite for sweets and palatable foods in particular, making CB1 an attractive therapeutic target for the treatment of obesity and eating disorders.7

ID gène: 25248

UniProt: P20272

Pathways: Feeding Behaviour